The primary antibodies used were rabbit polyclonal anti-phospho-ERK1/2 antibody (1:150; Phospho-p44/42 MAP kinase antibody, 9101S, Cell Signaling Technology, Danvers, MA, USA; [9 (link),10 (link)]), rabbit polyclonal anti-N-cadherin antibody (1/200; ab12221, Abcam, Cambridge, UK; [4 (link)], mouse monoclonal anti-β-catenin antibody (1:1000; C7207, Sigma-Aldrich; Saint Louis, MO, USA, [13 (link)]) and mouse monoclonal anti-RPE65 antibody (1:1000; MAB5428, Millipore; Billerica, MA, USA, [2 (link)]). The secondary antibodies used were biotinylated goat anti-rabbit IgG antibody (1:400; BA-1000, Vector Laboratories, Burlingame, CA, USA), biotinylated goat anti-mouse IgG antibody (1:400; BA-9200, Vector Laboratories, Burlingame, CA, USA), Alexa 488-conjugated goat anti-rabbit IgG antibody (1:500; A-11034, Thermo Fisher Scientific, Waltham, MA, USA) and tetramethylrhodamine-conjugated goat anti-mouse IgG antibody (1:200; T2762, Life Technologies, Rockville, MD, USA).
Free full text: Click here